Hu Xin, Ouyang Menglu, Xu Jianguo, Liu Yi, Li Xi, Jiang Yan, Chen Xiaoying, Billot Laurent, Li MBiostat Qiang, Malavera Alejandra, Venturelli Paula Muà Oz, de Silva Asita, Thang Nguyen Huy, Wahab Kolawole W, Pandian Jeyaraj D, Wasay Mohammad, Pontes-Neto Octavio M, Abanto Carlos, Arauz Antonio, Li Zongping, Chen Minhui, Wang Xiaofeng, Yang Chengyi, Xin Xiaodong, Jiang Dehua, Zheng Jun, Yu Zhiyuan, Xiao Anqi, Tao Chuanyuan, Chen Lei, Wu Bo, Li Hao, Anderson Craig S, You Chao, Song Lili, Ma Lu
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Lancet Reg Health West Pac. 2025 Aug 28;62:101669. doi: 10.1016/j.lanwpc.2025.101669. eCollection 2025 Sep.
There is ongoing controversy as to whether surgical intervention to haematoma evacuation benefits patients with acute intracerebral haemorrhage (ICH). This study aimed to evaluate the association of surgical intervention to evacuate the haematoma and 6-month functional outcome in participants of the third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3).
This was a secondary analysis of INTERACT3, which enrolled adults (age ≥18 years) spontaneous ICH patients within 6 h after onset. INTERACT3 was an international, multicentre, prospective, stepped-wedge, cluster randomised, blinded outcome assessed, clinical trial undertaken at 121 hospitals in 10 countries between December 12, 2017 and December 31, 2021. To limit heterogeneity in the results, we restricted analyses to participants in China. The primary outcome was poor functional outcome, defined by a score of 5-6 on the modified Rankin scale (mRS), at 6 months. Secondary outcomes include a mRS score of 4-6 and mortality at 6 months. Sensitivity analysis included propensity score matched analysis and the imputation of missing outcome variables. The effect of timing on surgical outcome was also evaluated. The INTERACT3 trial was registered at ClinicalTrials.gov (NCT03209258) and CHiCTR.org.cn (ChiCTR-IOC-17011787).
Of 5772 participants (mean age 62.0 ± 12.5 years) at 82 sites in China, 1411 (24.4%) received surgery in which craniotomy (72.6%) was the most common approach. After adjustment for confounding variables, surgery to evacuate the haematoma was associated with lower odds of a poor functional outcome (odds ratio 0.71, 95% CI 0.55-0.92; p = 0.010) and mortality (odds ratio 0.55, 95% CI 0.40-0.75; p = 0.0001) at 6 months. The association was consistent in propensity score matching analysis and sensitivity analysis by imputation. We did not detect significant differences in outcome between those who received surgery on the same day of hospital arrival compared to those who received surgery on the second or later days. In analysis limited to participants with supratentorial ICH and with a haematoma volume 30 mL or more, evacuation of the haematoma was associated with lower odds of poor functional outcome (n = 1234, odds ratio 0.68, 95% CI 0.46-0.99; p = 0.042) and mortality (n = 1291, OR 0.45, 95% CI 0.29-0.69; p = 0.0003).
This secondary analysis of the INTERACT3 indicates that evacuation of the haematoma is associated with better chances of surviving free of severe disability after acute ICH. With the evolution of instrument and techniques, further trial should address the role of haematoma evacuation in deep ICH patients, the time window and difference between mini-invasive techniques.
Joint Global Health Trials (JGHT) funding scheme from the Department of Health and Social Care, the Foreign, Commonwealth & Development Office, the Medical Research Council and Wellcome Trust; the West China Hospital Outstanding Discipline Development 1-3-5 programme; National Health and Medical Research Council of Australia; Sichuan Credit Pharmaceutical; and Takeda (China).
对于手术干预清除血肿是否对急性脑出血(ICH)患者有益,目前仍存在争议。本研究旨在评估在急性脑出血降压治疗强化护理包试验(INTERACT3)的参与者中,手术干预清除血肿与6个月功能结局之间的关联。
这是对INTERACT3的二次分析,该试验纳入了发病6小时内的成年(年龄≥18岁)自发性ICH患者。INTERACT3是一项国际多中心前瞻性阶梯楔形整群随机双盲结局评估临床试验,于2017年12月12日至2021年12月31日在10个国家的121家医院进行。为限制结果的异质性,我们将分析限制在中国的参与者中。主要结局是6个月时改良Rankin量表(mRS)评分为5 - 6分定义的功能结局不良。次要结局包括6个月时mRS评分为4 - 6分以及死亡率。敏感性分析包括倾向评分匹配分析和缺失结局变量的插补。还评估了时间对手术结局的影响。INTERACT3试验已在ClinicalTrials.gov(NCT03209258)和CHiCTR.org.cn(ChiCTR - IOC - 17011787)注册。
在中国82个研究点的5772名参与者(平均年龄62.0±12.5岁)中,1411名(24.4%)接受了手术,其中开颅手术(72.6%)是最常见的方法。在调整混杂变量后,手术清除血肿与6个月时功能结局不良(优势比0.71,95%可信区间0.55 - 0.92;p = 0.010)和死亡率(优势比0.55,95%可信区间0.40 - 0.75;p = 0.0001)的较低几率相关。在倾向评分匹配分析和插补敏感性分析中,该关联是一致的。我们未发现入院当天接受手术的患者与第二天或更晚接受手术的患者在结局上有显著差异。在仅限于幕上ICH且血肿体积≥30ml的参与者的分析中,清除血肿与功能结局不良(n = 1234,优势比0.68,95%可信区间0.46 - 0.99;p = 0.042)和死亡率(n = 1291,优势比0.45,95%可信区间0.29 - 0.69;p = 0.0003)的较低几率相关。
对INTERACT3的这项二次分析表明,清除血肿与急性ICH后存活且无严重残疾的更好机会相关。随着仪器和技术的发展,进一步的试验应探讨血肿清除在深部ICH患者中的作用、时间窗以及微创技术之间的差异。
英国卫生和社会保健部、外交、联邦和发展办公室、医学研究理事会以及惠康基金会的联合全球健康试验(JGHT)资助计划;华西医院杰出学科发展1 - 3 - 5计划;澳大利亚国家卫生与医学研究理事会;四川科伦药业;以及武田(中国)。